Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

By Oculis Holding AG | March 06, 2026, 4:01 PM

Oculis Holding AG

ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

Mentioned In This Article

Oculis Holding AG

Latest News

Oct-29	Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit OCS GlobeNewswire
Oct-22	Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis OCS GlobeNewswire
Oct-20	Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting OCS GlobeNewswire
Oct-19	Oculis lýkur slembiroðun i PREDICT-1 skraningarrannsokninni a Licaminlimab við TNFR1-miðluðum augnþurrki OCS GlobeNewswire
Oct-19	Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease OCS GlobeNewswire
Oct-08	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Oct-07	Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day OCS GlobeNewswire
Oct-01	Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS OCS -6.21% GlobeNewswire
Sep-30	Oculis Announces Resignation of Lionel Carnot from Board of Directors OCS GlobeNewswire
Sep-17	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Aug-24	First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis OCS GlobeNewswire
Aug-14	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities OCS GlobeNewswire
Aug-10	Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company OCS GlobeNewswire
Aug-06	Oculis Reports Q2 2026 Financial Results and Provides Company Update OCS GlobeNewswire
Aug-05	Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result OCS GuruFocus.com

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)